Psilocybin Shows Promise for Cocaine Use Disorder in Landmark JAMA Study

For decades, cocaine use disorder has stubbornly resisted pharmacological intervention. While behavioral therapies like contingency management offer modest benefits, no FDA-approved medication exists specifically for cocaine addiction—a gap that leaves millions of Americans with limited options. A groundbreaking randomized trial published in JAMA Network Open suggests that psilocybin-assisted psychotherapy may finally shift this landscape, achieving abstinence rates that dwarf anything seen in previous pharmacological studies.

A Study Design Built for Rigor

The University of Alabama at Birmingham trial employed a quadruple-blind methodology—meaning participants, investigators, outcome assessors, and data analysts remained unaware of treatment assignments throughout. Forty adults with cocaine use disorder received either a single 25 mg dose of psilocybin per 70 kg body weight or an active placebo of 100 mg diphenhydramine, the latter chosen specifically because it produces noticeable but non-psychedelic effects that help preserve blinding integrity.

Both groups underwent manualized psychotherapy incorporating cognitive behavioral therapy principles alongside supportive elements. The protocol included approximately one month of preparatory sessions before dosing, followed by integration therapy afterward—a structure mirroring emerging standards in psychedelic-assisted treatment.

What distinguishes this trial extends beyond its methodological rigor. The study population represented a dramatic departure from typical psychedelic research demographics. Most participants were Black men with low socioeconomic status and histories of cocaine use spanning decades. This matters profoundly because psychedelic clinical trials have historically skewed toward affluent, educated, predominantly white participants. The UAB study deliberately recruited from communities bearing disproportionate cocaine-related harm yet typically excluded from experimental therapies.

Results That Demand Attention

The primary outcomes paint a striking picture. Participants receiving psilocybin demonstrated approximately 29 additional percentage points of cocaine-abstinent days across follow-up periods compared to the placebo group. More dramatically, 30% of psilocybin recipients achieved complete cocaine abstinence through 180 days—while zero participants in the placebo group met this threshold.

The hazard ratio of 0.28 for cocaine lapse indicates that psilocybin recipients faced roughly 72% lower risk of relapse over time. For a condition where existing pharmacotherapies have repeatedly failed to demonstrate meaningful efficacy, these figures represent a potential paradigm shift rather than incremental improvement.

Safety data further supported the intervention's viability. No serious adverse events were attributed to psilocybin administration. Most reported effects occurred during the dosing session itself—largely consisting of transient psychological phenomena expected with psychedelic compounds—and resolved without medical intervention. This safety profile, combined with the single-dose administration model, suggests practical feasibility if larger trials confirm efficacy.

The Neuroscience Behind the Promise

Psilocybin's therapeutic potential stems from its active metabolite psilocin, a serotonin 5-HT2A receptor agonist that produces profound alterations in consciousness lasting several hours. Beyond the acute psychedelic experience, research indicates these compounds enhance neuroplasticity—the brain's capacity to reorganize neural pathways in response to experience.

For addiction treatment, this neuroplastic window may prove crucial. Chronic cocaine use establishes deeply ingrained patterns of cue reactivity, craving, and compulsive drug-seeking that resist conventional interventions. Psilocybin appears to temporarily disrupt these rigid patterns while facilitating new perspectives on behavior, relationships, and personal values. Participants often describe their experiences as providing clarity about their addiction's costs or reconnecting with aspirations that substance use had obscured.

Previous studies have demonstrated psilocybin's efficacy in alcohol use disorder and tobacco dependence, suggesting cross-substance applicability. The current trial extends this evidence base to stimulant use disorders specifically, addressing a therapeutic area where need dramatically exceeds available options.

Critical Limitations and Cautious Interpretation

Despite encouraging signals, the study's authors appropriately emphasize constraints on interpretation. The sample size of forty participants, while standard for early-phase psychedelic research, limits statistical precision. Confidence intervals for some outcomes remain wide, reflecting uncertainty that only larger trials can resolve.

Blinding presented particular challenges inherent to psychedelic research. Psilocybin's pronounced psychoactive effects make functional unblinding virtually inevitable—participants typically know whether they received the active compound. While the diphenhydramine placebo produced noticeable effects, the qualitative difference between antihistamine sedation and psychedelic experience likely enabled many participants to infer their assignment. This limitation, common across psychedelic trials, complicates effect size estimation.

The study's duration, while substantial at 180 days, cannot establish long-term durability. Sustained abstinence beyond six months remains the critical benchmark for addiction treatment, and follow-up studies will need to track participants for years to assess whether initial gains persist.

What This Means for Treatment Access

For people struggling with stimulant addiction, these findings introduce genuine hope where pharmacological options have repeatedly disappointed. The absence of FDA-approved medications for cocaine use disorder has left behavioral interventions as the sole evidence-based approach—a limitation that psilocybin research may eventually address.

However, significant barriers separate these research findings from clinical availability. Psilocybin remains a Schedule I controlled substance under federal law, restricting its use to approved research protocols. The therapeutic model requiring extensive psychotherapy before and after dosing sessions differs fundamentally from conventional medication management, raising questions about scalability and cost if approved for clinical use.

The study's emphasis on recruiting underrepresented populations offers a template for addressing equity concerns that have plagued psychedelic research. If larger trials maintain this commitment and subsequent clinical implementation prioritizes access for communities historically excluded from innovative treatments, psilocybin could help address rather than exacerbate addiction treatment disparities.

The Broader Context of Psychedelic Medicine

This trial arrives amid accelerating interest in psychedelic-assisted therapies across psychiatry. FDA breakthrough therapy designations for psilocybin in treatment-resistant depression and MDMA in PTSD have created anticipation of potential approvals within coming years. The Trump administration's recent executive order prioritizing psychedelic research, including $50 million in federal funding and provisions for expanded access, signals growing institutional support.

Yet significant challenges remain. The FDA's rejection of MDMA-assisted therapy for PTSD in 2024—despite compelling trial data—demonstrated that regulatory pathways for psychedelic medicines remain uncertain. Manufacturing standards, therapist training requirements, and abuse liability assessments all require resolution before clinical integration becomes feasible.

For cocaine use disorder specifically, the UAB findings join a small but growing literature suggesting psychedelic-assisted approaches may succeed where conventional pharmacotherapy has failed. A 2024 trial from the same research group found promising signals in an open-label design; the current randomized controlled trial confirms and extends those observations with methodological rigor.

Looking Forward

The path from promising Phase II data to approved therapy typically requires larger confirmatory trials, potentially involving hundreds of participants across multiple sites. Given cocaine use disorder's substantial public health burden—overdose deaths involving stimulants have risen sharply even as opioid mortality has declined—the urgency for effective interventions justifies accelerated research investment.

Should larger trials replicate these findings, psilocybin would become the first pharmacological intervention demonstrating robust efficacy for cocaine addiction. The implications extend beyond individual patient outcomes to potentially reshape understanding of addiction itself—shifting conceptualization from chronic relapsing disease requiring ongoing medication toward conditions amenable to transformative experiences that catalyze lasting behavioral change.

For now, these results remain preliminary but profoundly encouraging. They suggest that after decades of frustration in developing pharmacological treatments for stimulant use disorders, a fundamentally different approach—one leveraging neuroplasticity and psychological insight rather than receptor blockade or substitution—may finally offer the breakthrough that patients and clinicians have sought.